Trial Profile
A Randomized, Placebo-Controlled, Double-Blind, Clinical Trial Evaluating Two Dose Regimens of Rifaximin (550 mg Daily or 550 mg Twice Daily) for Chemoprophylaxis Against Travelers' Diarrhea (TD) Among Active Duty Deployed U.S. and British Military Personnel
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 17 Feb 2023
Price :
$35
*
At a glance
- Drugs Rifaximin (Primary)
- Indications Reactive arthritis; Traveller's diarrhoea
- Focus Therapeutic Use
- 13 Feb 2023 Status changed from active, no longer recruiting to completed.
- 25 Nov 2019 Planned End Date changed from 1 Nov 2019 to 31 Dec 2021.
- 25 Nov 2019 Planned primary completion date changed from 1 Apr 2019 to 31 Dec 2019.